Renal transplant recipients and donors are becoming increasingly more marginal, with more expanded criteria (ECD) and donation after circulatory death (DCD) donors and increasingly older recipients with multiple comorbidities. Despite this, high-risk donors and recipients are often excluded from clinical trials, leading to uncertainty about the generalizability of findings. In order to highlight the extent of this […]
The October edition of the Transplant Trial Watch is now available on the CET website. Each month, our team summarise and assess the quality of 10 important randomised controlled trials in the field of solid organ transplantation. This month, trials include sirolimus in the prevention of skin cancer in transplant recipients, machine perfusion in extended […]
The September edition of the Transplant Trial Watch is now available on the CET website. Each month, the CET staff select 10 recently published randomised controlled trials in the field of transplantation and summarise the findings and quality. This month, the Trial Watch includes a trial of generic tacrolimus, long-term results from the Tricontinental MMF […]
Sylvie Euvrard and her colleagues (New England Journal of Medicine 2012; 367:329) have performed a multicentre randomised trial in patients on a calcineurin inhibitor who had developed at least 1 squamous cell cancer of the skin after renal transplantation. Patients were randomised to either continue on the calcineurin inhibitor or to be converted to sirolimus. […]